SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

23 Jan 2024 Evaluate
The revenue slipped marginally during the December 2023 quarter. A decline of about Rs. 1613.35 millions was observed as compared to Rs. 1687.92 millions during the corresponding quarter last year.The Net proft of the company remain more or less same to Rs. 207.19  millions from Rs. 292.80 millions ,decline by -29.24%.A decline of 365.56 millions was observed in the OP in the quarter ended December 2023 from 448.84 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 1613.35 1687.92 -4.42 4416.42 4549.21 -2.92 5983.40 6363.57 -5.97
Other Income 78.97 114.23 -30.87 250.38 442.88 -43.47 507.66 326.28 55.59
PBIDT 365.56 448.84 -18.55 1070.56 1235.31 -13.34 1409.21 1418.26 -0.64
Interest 17.88 12.03 48.63 42.75 50.84 -15.91 100.57 43.24 132.59
PBDT 347.68 436.81 -20.40 1027.81 1184.47 -13.23 1308.64 1402.47 -6.69
Depreciation 62.48 37.90 64.85 172.90 111.99 54.39 151.73 138.47 9.58
PBT 285.20 398.91 -28.51 854.91 1072.48 -20.29 1156.91 1264.00 -8.47
TAX 78.01 106.11 -26.48 233.85 278.77 -16.11 302.14 337.36 -10.44
Deferred Tax 13.84 -12.71 -208.89 22.13 -17.41 -227.11 -42.10 7.68 -648.18
PAT 207.19 292.80 -29.24 621.06 793.71 -21.75 854.77 926.64 -7.76
Equity 104.69 104.15 0.52 104.69 104.15 0.52 104.15 103.68 0.45
PBIDTM(%) 22.66 26.59 -14.79 24.24 27.15 -10.73 23.55 22.29 5.68

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×